Prophylactic GvHD treatment with ATLG in patients with myelofibrosis

The study found that the cumulative incidence of acute GvHD (aGvHD) Grade II–IV (30% vs 56%; p < 0.001), aGvHD Grade III–IV (20% vs 25%; p = 0.01), and severe chronic GvHD (cGvHD; 7% vs 18%; p = 0.04) was lower in the ATLG cohort (n = 469) vs the no ATLG cohort (n = 238), while the incidences of mild-to-severe cGvHD were similar (49% vs 50%; p = 0.52). 

ATLG treatment was associated with a notable improvement in the estimated GvHD-free and relapse-free survival (GRFS) at 3 years (53% vs 47%; p = 0.04) and 6 years (45% vs 37%; p = 0.02), particularly in patients with matched related or unrelated donors. 

Despite the benefits in reducing GvHD and improving GRFS, there were no significant differences between the ATLG and no ATLG cohorts in terms of estimated overall survival at 6 years (64% vs 60%; p = 0.53), cumulative incidences of relapse at 6 years (12% vs 15%; p = 0.62), and non-relapse mortality at 1 year (20% vs 19%; p = 0.80) and 3 years (27% vs 29%; p = 0.55).